A61K 48/0075
Medicinal preparations containing genetic material which is inserted into cells of the
Official title: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
A61K48/0075 (Medicinal preparations containing genetic material which is inserted into cells of the) appears on 867 US grants and 2,367 published applications in this corpus.
Search patents in A61K- Granted patents
- 867
- Published applications
- 2,367
- Assignees
- 752
- Inventors
- 3,398
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 2 |
| 2002 | 2 | 25 |
| 2003 | 11 | 28 |
| 2004 | 5 | 41 |
| 2005 | 7 | 39 |
| 2006 | 7 | 40 |
| 2007 | 14 | 38 |
| 2008 | 7 | 35 |
| 2009 | 14 | 39 |
| 2010 | 21 | 35 |
| 2011 | 11 | 35 |
| 2012 | 22 | 38 |
| 2013 | 14 | 44 |
| 2014 | 21 | 79 |
| 2015 | 38 | 54 |
| 2016 | 44 | 123 |
| 2017 | 41 | 87 |
| 2018 | 34 | 110 |
| 2019 | 54 | 164 |
| 2020 | 57 | 148 |
| 2021 | 78 | 153 |
| 2022 | 62 | 180 |
| 2023 | 64 | 153 |
| 2024 | 73 | 226 |
| 2025 | 87 | 261 |
| 2026 | 66 | 190 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Expression of the human lekti gene from the chromosome of Staphylococcus epidermidis29 Sep 2026US 12,747,281 B2Azitra Inc
- Riboswitch modulated gene therapy for retinal diseases29 Sep 2026US 12,747,441 B2The Medical College of Wisconsin, Inc.
- Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems22 Sep 2026US 12,741,034 B2Decibel Therapeutics, Inc.
- Utilization of gene targeting antibody fusion proteins to perform in vivo therapeutic gene editing22 Sep 2026US 12,741,035 B2Baylor College of Medicine
- Formulations comprising recombinant aav and methods of administering the same8 Oct 2026US 2026/0306663 A1Ultragenyx Pharmaceutical Inc.
- Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies8 Oct 2026US 2026/0306664 A1AbbVie Inc.
- Methods of treating neurodegenerative disorders8 Oct 2026US 2026/0306669 A1
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Transcription factor 4 gene editing system8 Oct 2026US 2026/0306671 A1The Regents of the University of California
Most cited
By later US patents
- Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor615US 5,328,470 AThe Regents of the University of Michigan · 1994
- Engineered nucleic acids and methods of use thereof372US 8,822,663 B2Moderna Therapeutics, Inc. · 2014
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012
- RNA containing modified nucleosides and methods of use thereof230US 8,691,966 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof222US 8,748,089 B2The Trustees of the University of Pennsylvania · 2014